- Report
- October 2024
- 188 Pages
Global
From €3348EUR$3,545USD£2,848GBP
€3720EUR$3,939USD£3,164GBP
- Report
- February 2025
- 182 Pages
Global
From €4250EUR$4,500USD£3,615GBP
- Report
- January 2025
- 120 Pages
United States
From €2352EUR$2,490USD£2,000GBP
- Report
- March 2024
- 71 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
Rocuronium is a neuromuscular blocking drug used in anesthetic drugs to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a non-depolarizing neuromuscular blocker, meaning it does not cause muscle contraction, but instead blocks the transmission of nerve impulses to the muscle. It is commonly used in combination with other anesthetic drugs, such as propofol, to provide a smooth and safe intubation process.
Rocuronium is available in both generic and branded forms, and is widely used in hospitals and other medical settings. It is also used in veterinary medicine, and is available in a variety of formulations, including injectable, oral, and topical.
The rocuronium market is highly competitive, with a number of companies offering products. Some of the major players in the market include Mylan, Pfizer, Fresenius Kabi, Hospira, and Teva Pharmaceuticals. Show Less Read more